Chimeric antigen recipient cell targeting human CD33 and NKG2DL as well as preparation method and application of chimeric antigen recipient cell
The invention belongs to the field of chimeric antigen recipient cells, and relates to a chimeric antigen recipient cell targeting human CD33 and NKG2DL as well as a preparation method and application thereof, and the chimeric antigen recipient cell contains amino acid sequences targeting binding hu...
Gespeichert in:
Hauptverfasser: | , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention belongs to the field of chimeric antigen recipient cells, and relates to a chimeric antigen recipient cell targeting human CD33 and NKG2DL as well as a preparation method and application thereof, and the chimeric antigen recipient cell contains amino acid sequences targeting binding human CD33 and targeting binding human NKG2DL. The immune response cell modified by the bispecific chimeric antigen receptor targeting CD33 and NKG2DL can enhance the combination with tumor cells, and has obvious anti-tumor activity in tumors expressing human CD33/NKG2DL antigens, such as acute myelogenous leukemia (AML).
本发明属于嵌合抗原受体细胞领域,一种靶向人CD33和NKG2DL的嵌合抗原受体细胞及其制备方法和应用,该嵌合抗原受体细胞含有靶向结合人CD33和靶向结合人NKG2DL的氨基酸序列。本发明的靶向CD33和NKG2DL的双特异性嵌合抗原受体修饰的免疫应答细胞能增强与肿瘤细胞的结合,在表达人CD33/NKG2DL抗原肿瘤如急性髓系白血病AML中有明显抗肿瘤活性。 |
---|